PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndrome

被引:8
|
作者
Lewis, Natasha E. [1 ]
Gao, Qi [1 ]
Petrova-Drus, Kseniya [1 ,2 ]
Pulitzer, Melissa [3 ]
Sigler, Allison [1 ]
Baik, Jeeyeon [1 ]
Moskowitz, Alison J. [4 ]
Horwitz, Steven M. [4 ]
Dogan, Ahmet [1 ]
Roshal, Mikhail [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, Hematopathol Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, Diagnost Mol Pathol Serv, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, Dermatopathol Serv, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY 10065 USA
关键词
flow cytometry; mycosis fungoides; PD-1; Sezary syndrome; PROGRAMMED DEATH-1; DIFFERENTIAL EXPRESSION; T-CELLS; LYMPHOMA; CLASSIFICATION; CLONALITY; BIOPSIES; PATHWAY; MARKERS;
D O I
10.1002/cyto.b.22070
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background Accurate Sezary cell detection in peripheral blood of mycosis fungoides/Sezary syndrome (MF/SS) patients by flow cytometry can be difficult due to overlapping immunophenotypes with normal T cells using standard markers. We assessed the utility of programmed death-1 (PD-1/CD279), a transmembrane protein expressed in some hematopoietic cells, for identification and quantitation of circulating Sezary cells among established markers using flow cytometry. Methods 50 MF/SS and 20 control blood samples were immunophenotyped by flow cytometry. Principal component analysis (PCA) assessed contributions of antigens to separation of abnormal from normal T cell populations. PD-1 was assessed over time in blood and bone marrow of available MF/SS cases. Results Normal CD4+ T cells showed dim/intermediate to absent PD-1 expression. PD-1 in Sezary cells was informatively brighter (>= 1/3 log) than internal normal CD4+ T cells in 39/50 (78%) cases. By PCA, PD-1 ranked 3rd behind CD7 and CD26 in population separation as a whole; it ranked in the top 3 markers in 32/50 (64%) cases and 1st in 4/50 (8%) cases when individual abnormal populations were compared to total normal CD4+ T cells. PD-1 clearly separated Sezary from normal CD4+ T cells in 15/26 (58%, 30% of total) cases with few and subtle alterations of pan-T cell antigens/CD26 and was critical in 6 (12% of total), without which identification and quantification were significantly affected or nearly impossible. PD-1 remained informative in blood/bone marrow over time in most patients. Conclusions PD-1 significantly contributes to accurate flow cytometric Sezary cell assessment in a routine Sezary panel.
引用
收藏
页码:189 / 198
页数:10
相关论文
共 50 条
  • [31] PD-1 overexpression in Sezary syndrome is epigenetically regulated
    Najidh, S.
    Zoutman, W. H.
    Tensen, C. P.
    Vermeer, M. H.
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S2 - S2
  • [32] The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome
    Papadavid, E
    Economidou, J
    Psarra, A
    Kapsimali, V
    Mantzana, V
    Antoniou, C
    Limas, K
    Stratigos, A
    Stavrianeas, N
    Avgerinou, G
    Katsambas, A
    BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (04) : 709 - 718
  • [33] Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sezary syndrome
    Wada, David A.
    Wilcox, Ryan A.
    Harrington, Susan M.
    Kwon, Eugene D.
    Ansell, Stephen M.
    Comfere, Nneka I.
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (03) : 325 - 327
  • [34] CADM1: A molecule worth investigating in mycosis fungoides and Sezary syndrome
    Zhang, Shiyu
    Wang, Tao
    Liu, Yuehua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (04) : E141 - E142
  • [35] The value of five blood markers in differentiating mycosis fungoides and Sezary syndrome: a validation cohort
    Dobos, G.
    De Cevins, C.
    So, S. Ly Ka
    Jean-Louis, F.
    Mathieu, S.
    Ram-Wolff, C.
    Resche-Rigon, M.
    Bensussan, A.
    Bagot, M.
    Michel, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (02) : 405 - 411
  • [36] Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sezary syndrome
    Beylot-Barry, Marie
    Booken, Nina
    Weishaupt, Carsten
    Scarisbrick, Julia
    Wu, Wende
    Rosen, Jan-Paul
    Medley, Michael C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (02) : 311 - 316
  • [37] Changes in blood involvement in Sezary syndrome positively correlate with skin severity but not in mycosis fungoides
    Wernham, A.
    Stranzenbach, R.
    Stadler, R.
    Ortiz, P.
    Guenova, E.
    Quaglino, P.
    Hodak, E.
    Papadavid, E.
    Wehkamp, U.
    Evison, F.
    Bagot, M.
    Scarisbrick, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S92 - S92
  • [38] It is time to adopt a multicolor immunophenotyping approach to evaluate blood for Sezary syndrome and mycosis fungoides
    Craig, Fiona E.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2021, 100 (02) : 125 - 128
  • [39] DETECTION OF CLONAL T-CELL RECEPTOR GENE REARRANGEMENTS IN THE PERIPHERAL-BLOOD OF PATIENTS WITH MYCOSIS-FUNGOIDES SEZARY SYNDROME
    WEISS, LM
    WOOD, GS
    HU, E
    ABEL, EA
    HOPPE, RT
    SKLAR, J
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1989, 92 (04) : 601 - 604
  • [40] Molecular detection of circulating Sezary cells in patients with mycosis fungoides: could it predict future development of secondary Sezary syndrome? A single-institution experience
    Hutchinson, Charles Blake
    Stoecker, Maggie
    Wang, Frances F.
    Papalas, John
    Sebastian, Siby
    Burchette, James
    Datto, Michael
    Wang, Endi
    LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 868 - 877